Reviewing Aeglea BioTherapeutics Inc. (AGLE)’s and Bio-Techne Corporation (NASDAQ:TECH)’s results

Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) and Bio-Techne Corporation (NASDAQ:TECH) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aeglea BioTherapeutics Inc. 2.38M 74.00 53.40M -2.21 0.00
Bio-Techne Corporation 702.60M 11.61 121.21M 3.10 63.51

Table 1 demonstrates Aeglea BioTherapeutics Inc. and Bio-Techne Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Aeglea BioTherapeutics Inc. -2,243.70% -66.6% -59.8%
Bio-Techne Corporation 17.25% 11% 6.8%

Liquidity

10.7 and 10.7 are the respective Current Ratio and a Quick Ratio of Aeglea BioTherapeutics Inc. Its rival Bio-Techne Corporation’s Current and Quick Ratios are 4.3 and 3.4 respectively. Aeglea BioTherapeutics Inc. has a better chance of clearing its pay short and long-term debts than Bio-Techne Corporation.

Dividends

Meanwhile, Bio-Techne Corporation’s annual dividend is $1.28 per share and it also boasts of a 0.6% dividend yield. No dividend is paid out for Aeglea BioTherapeutics Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Aeglea BioTherapeutics Inc. and Bio-Techne Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aeglea BioTherapeutics Inc. 0 0 1 3.00
Bio-Techne Corporation 0 0 2 3.00

$14 is Aeglea BioTherapeutics Inc.’s average target price while its potential upside is 129.51%. Competitively the average target price of Bio-Techne Corporation is $205, which is potential -4.84% downside. The results provided earlier shows that Aeglea BioTherapeutics Inc. appears more favorable than Bio-Techne Corporation, based on analyst belief.

Insider & Institutional Ownership

The shares of both Aeglea BioTherapeutics Inc. and Bio-Techne Corporation are owned by institutional investors at 67.4% and 95% respectively. Aeglea BioTherapeutics Inc.’s share owned by insiders are 1%. Competitively, insiders own roughly 0.38% of Bio-Techne Corporation’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aeglea BioTherapeutics Inc. -0.58% -5.79% -13.54% -24.95% -33.5% -8.81%
Bio-Techne Corporation -2.6% -1.96% 4.04% 15.15% 29.42% 35.9%

For the past year Aeglea BioTherapeutics Inc. had bearish trend while Bio-Techne Corporation had bullish trend.

Summary

On 10 of the 13 factors Bio-Techne Corporation beats Aeglea BioTherapeutics Inc.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.